-$1.3M
Net insider buying / selling at West Pharmaceutical Services (WST) over the last 2 years. Updated Apr 29, 2026

Are West Pharmaceutical Services Insiders Buying or Selling?

West Pharmaceutical Services (WST) has had no reported insider transactions in the past 90 days. The most recent was Annette Favorite, who sold 2,817 shares at $305.20 on April 27, 2026.

Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the WST AI Score. For government officials trading this stock, see WST congressional trading.

Who’s Trading West Pharmaceutical Services Stock?

InsiderActivityTradesLast Trade
Annette Favorite Sold $860,000 1 Apr 27, 2026
Chad Winters Sold $270,000 1 Apr 27, 2026
Charles Witherspoon Sold $220,000 2 Oct 29, 2024

Recent West Pharmaceutical Services Insider Transactions

Insider Transaction Date Type Shares Price Value
Annette FavoriteApr 27, 2026Sell2,817$305.2$860,000
Chad WintersApr 27, 2026Sell896$300.67$270,000
Charles WitherspoonOct 29, 2024Sell478$310.4$150,000
Charles WitherspoonOct 29, 2024Sell225$310.4$70,000

Frequently Asked Questions: West Pharmaceutical Services Insider Trading

West Pharmaceutical Services insiders have not reported any transactions in the past 90 days.

The most recent sale was by Annette Favorite who sold 2,817 shares on April 27, 2026. View all transactions in the table on this page.

Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.

Favorite Annette F has sold the most WST stock in the last 2 years, with a total value of $860,000.

The total value of insider transactions for West Pharmaceutical Services in the last 2 years is negative, amounting to -$1.3M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.